Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albuterol eMDPI in COPD Exacerbations
NCT03256695Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Sep 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of albuterol spiromax in chronic obstructive pulmonary disease (COPD), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Percentage of Participants Who Experienced at Least 1 Moderate or Severe CE-COPD at 12 weeks, Total Number of Albuterol Inhalations in the Days Preceding the Symptom Peak of a CE-COPD Event at 12 weeks and 2 more. Started Sep 2017; status: completed.
02
Drugs
albuterol spiromax
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03256695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03256695.